Variant Pharmaceuticals Has a New Name - ZyVersa Therapeutics, Inc.
FSGS is a progressive form of kidney disease associated with accumulation of cholesterol and lipids in the section of the kidneys (glomeruli) that filters wastes out of the blood& for excretion as urine. Damage to the glomeruli causes protein to leak into the urine, a condition known as proteinuria. High levels of protein in the urine are associate with a specific set of symptoms, known as nephrotic syndrome. In addition to the high levels of protein in the urine, symptoms of nephrotic syndrome include lower than normal levels of albumin (a protein) in the blood (hypoalbuminemia), swelling, especially in the legs, and high blood pressure (hypertension). The hypertension in people with FSGS can often be very difficult to treat. The level of proteinuria greatly influences FSGS outcomes, and the prognosis is poor for those with nephrotic syndrome1-3.
70% of FSGS patients present with nephrotic syndrome
FSGS Returns in 30%-40% of patients after kidney transplant
FSGS is estimated to affect up to 80,000 people in the United States4, with more than 5,400 new cases diagnosed annually5. FSGS is most common in adults 18-45 years, and its occurrence is 3-4 times more common in men than women. FSGS occurs in Blacks at a rate that is 7 times higher than in Caucasians3.
At present, there are no specific treatments for FSGS and there is no cure. Current therapy focuses on maintaining adequate nutrition, controlling blood pressure and serum lipids, minimizing loss of protein in the urine, and preventing complications from edema, thereby stabilizing kidney function.
There is a significant unmet need for effective FSGS-specific treatments that can delay disease progression, prevent end-stage renal disease, and improve patients' quality of life.